Hilde Furberg
Director/Board Member chez SEDANA MEDICAL AB
Fortune : 564 200 $ au 31/03/2024
Profil
Hilde Furberg is currently an Independent Director at PCI Biotech Holding ASA, an Independent Non-Executive Director at Calliditas Therapeutics AB, an Independent Director at Herantis Pharma Oyj, a Director at Sedana Medical AB, and a Director at Pluvia AS.
She previously held positions as the SVP-Personalized Genetic Health Europe at Genzyme Europe BV and as a Partner at J&J Future Invest AS.
Furberg has also served as the Chairman of Blueprint Genetics Oy, an Independent Director at Probi AB, a Director at Copenhagen Capacity, a Director at Pronova BioPharma ASA, an Independent Director at Weifa ASA, a Non-Executive Director at Algeta ASA, an Independent Non-Executive Director at BerGenBio ASA, and a Director at CombiGene AB, Bio-Me AS, and Tappin AS.
Additionally, she has been a Director at OncoZenge AB since 2020.
Furberg's education includes a graduate degree from the University of Oslo in 1980.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/02/2023 | 53 199 ( 0,09% ) | 564 200 $ | 31/03/2024 |
Postes actifs de Hilde Furberg
| Sociétés | Poste | Début |
|---|---|---|
| CALLIDITAS THERAPEUTICS AB | Director/Board Member | 01/12/2016 |
| PCI BIOTECH HOLDING ASA | Director/Board Member | 01/05/2019 |
| HERANTIS PHARMA OYJ | Director/Board Member | 15/04/2021 |
| SEDANA MEDICAL AB | Director/Board Member | 01/01/2022 |
J&J Future Invest AS
 J&J Future Invest AS Real Estate DevelopmentFinance J & J Future Invest AS is a Norwegian company that operates a real estate agency. | Corporate Officer/Principal | - |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Corporate Officer/Principal | 14/10/2011 |
Pluvia AS
 Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | Director/Board Member | - |
Anciens postes connus de Hilde Furberg
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOZENGE AB | Director/Board Member | 21/08/2023 |
| BERGENBIO ASA | Chairman | 06/01/2017 |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Hilde Furberg
| University of Oslo | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 8 |
|---|---|
| PROBI AB | Health Technology |
| PCI BIOTECH HOLDING ASA | Health Technology |
| CALLIDITAS THERAPEUTICS AB | Health Technology |
| BERGENBIO ASA | Health Technology |
| HERANTIS PHARMA OYJ | Health Technology |
| COMBIGENE AB | Health Technology |
| SEDANA MEDICAL AB | Health Technology |
| ONCOZENGE AB | Health Technology |
| Entreprise privées | 12 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Copenhagen Capacity
 Copenhagen Capacity Financial ConglomeratesFinance Copenhagen Capacity provides investment promotion and economic development services. The private company is based in Copenhagen, Denmark. Asbjørn Overgaard Christiansen has been the CEO of the Danish company since 2020. | Finance |
Pronova BioPharma ASA
 Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | Health Technology |
Weifa ASA
 Weifa ASA Pharmaceuticals: MajorHealth Technology Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway. | Health Technology |
Genzyme Europe BV
Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Health Technology |
| Baxter Medical AB | |
Blueprint Genetics Oy
 Blueprint Genetics Oy BiotechnologyHealth Technology Blueprint Genetics Oy engages in the provision of genetic diagnostics and clinical interpretation of hereditary diseases. It offer dignistic tests for cardiology; dermatology; endocrinology; immunology; metabolic disorder; nephrology; and pulmonology. The company was founded by Tommi Pietari Lehtonen, Juha Koskenvuo, Tero-Pekka Alastalo, and Samuel Myllykangas in 2008 and is headquartered in Helsinki, Finland. | Health Technology |
Pluvia AS
Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | Commercial Services |
Bio-Me AS
 Bio-Me AS BiotechnologyHealth Technology Bio-Me AS operates as a boi-tech firm. It researches and develops patented technologies and new approaches in bacteria analysis. The company is headquartered in Oslo, Norway. | Health Technology |
J&J Future Invest AS
J&J Future Invest AS Real Estate DevelopmentFinance J & J Future Invest AS is a Norwegian company that operates a real estate agency. | Finance |
| Tappin AS | |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
